Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021.
Merck and BioNTech are further expanding their strategic partnership. Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech Covid-19 Vaccine (BNT162b2).
Lipids are critical to the drug delivery system of mRNA therapies to the body for a vaccine to be effective. Only very few companies in the world are currently able to produce custom lipids in significant quantities and according to the highest quality requirements needed for vaccine production.
“What unites BioNTech and Merck is our strong belief in mRNA technology and our trustful collaboration in vaccine development. We are convinced that now is the time to pull together to supply as much vaccine as possible to the world. Extraordinary times like these require bold steps, and we are ready to take these steps to tackle one of the biggest challenges of humanity”, said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
With the outbreak of the pandemic, Merck and BioNTech had started to intensify their previously existing collaboration.
In the past weeks, Merck has been working hard to expand its already very high lipid production capacity. This required the further development of production technologies and the implementation of new, highly complex process steps. BioNTech and Merck are currently defining exact requirements and are aiming for a timely execution of their joint efforts.
Merck is a global leader in lipids. The company has extensive expertise in providing custom lipids and other critical components such as synthetic cholesterol for lipid nanoparticle formulations. Merck is active across multiple steps of the process flow and collaborates with many companies using lipid-based technologies to address Covid-19 vaccines and treatment.
Support of more than 50 vaccine projects worldwide
Since the outbreak of the pandemic, Merck has been intensely involved in the fight against the coronavirus. The Life Science business sector is supporting more than 50 vaccine projects worldwide with products and technologies. The company’s role is comparable to that of a supplier in the automotive sector.
Depending on the project, Merck supports the research and development process, for which it offers raw materials and products such as proteases or antibodies. The company also offers a full spectrum of products used throughout the subsequent manufacturing processes for Covid-19 vaccines.
Because vaccine manufacturing is very complex and no standardized processes for innovative vaccines exist, Merck supports its customers in developing customized manufacturing platforms that enable industrial-scale production. Many Merck products are used for this purpose, for example single-use assemblies, systems for biopharmaceutical production and consumables.
Integrated offering across the mRNA value chain
With the acquisition of AmpTec, announced in early January, Merck has further strengthened its capabilities and capacities for the development and production of mRNA. In particular, the combination of AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing makes it possible to provide a truly integrated offering across the mRNA value chain.
In addition to vaccine development and production, Merck also supports more than 35 Covid-19 testing solutions and is collaborating with many clinical laboratories and diagnostics manufacturers. The company supplies critical raw materials across all key steps involved in diagnosing Covid-19 infections with PCR tests, such as oligonucleotide primers. In addition, it manufactures key products such as Hi-Flow membranes, for serologicals that enable testing for the presence of Covid-19 antibodies.
The Pfizer-BioNTech Covid-19 Vaccine (BNT162b2), which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, the United Kingdom, Canada, and other countries. It has been authorized for use by the health regulatory authorities of about 50 countries, including Switzerland and the European Union member states where it has been granted Conditional Marketing Authorization, and it has received authorizations for emergency use in e.g. the United Kingdom, the United States, and Canada. According to the data from the global Phase III clinical trial, the vaccine met all primary efficacy endpoints, demonstrating effectiveness of 95% in preventing Covid-19 in adults and 94% in adults over 65 years of age.
Thomas Möller, photo Merck